STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGEN
  4. [Form 4] REPLIGEN CORP Insider Trading Activity

Repligen (NASDAQ: RGEN) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corporation director Konstantin Konstantinov received new equity awards consisting of restricted stock units and stock options. He was granted 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 3,889 shares after the award.

He was also granted stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, with the options expiring on May 14, 2036. Both the restricted stock units and the option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of shareholders.

Positive

  • None.

Negative

  • None.
Insider Konstantinov Konstantin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,239 $0.00 --
Grant/Award Common Stock 995 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,239 shares (Direct, null); Common Stock — 3,889 shares (Direct, null)
Footnotes (1)
  1. Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
RSUs granted 995 units Restricted stock units granted to director on May 14, 2026
Common shares held after grant 3,889 shares Director’s direct common stock holdings following RSU award
Options granted 2,239 shares Stock option award covering Repligen common stock
Option exercise price $103.38 per share Exercise price for 2,239 stock options
Option expiration May 14, 2036 Expiration date of granted stock options
Vesting date trigger May 14, 2027 or next annual meeting Vesting schedule for RSUs and options
restricted stock units financial
"Mr. Konstantinov was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: "103.3800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"Award vests in full on the earlier of May 14, 2027"
annual meeting of the Company's shareholders financial
"or on the date of the next annual meeting of the Company's shareholders"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Konstantinov Konstantin
(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A995(1)A$0.003,889D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$103.3805/14/2026A2,23905/14/2027(2)05/14/2036Common Stock2,239$0.002,239D
Explanation of Responses:
1. Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Jennifer Carmichael (Attorney in Fact)05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Repligen (RGEN) director Konstantin Konstantinov receive in this Form 4 filing?

Konstantin Konstantinov received equity compensation consisting of 995 restricted stock units and stock options on 2,239 shares. These awards increase his direct equity exposure to Repligen and are structured to vest based on time and the next annual shareholder meeting.

How many Repligen (RGEN) shares does Konstantin Konstantinov hold after this grant?

After the grant, Konstantin Konstantinov directly holds 3,889 shares of Repligen common stock. In addition, he holds options on 2,239 shares, which may be exercised at a fixed price once they vest, further linking his compensation to future share performance.

What are the terms of the Repligen (RGEN) stock options granted to Konstantin Konstantinov?

Konstantin Konstantinov received stock options on 2,239 Repligen shares at an exercise price of $103.38 per share. These options vest in full on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and expire on May 14, 2036.

How do the restricted stock units for Repligen (RGEN) vest for Konstantin Konstantinov?

The 995 restricted stock units vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual shareholder meeting. Each unit settles into one share of common stock upon vesting, delivered in shares only.

Are the new Repligen (RGEN) equity awards to Konstantin Konstantinov open-market purchases or compensation grants?

The awards are compensation-related grants, not open-market purchases. Both the 995 restricted stock units and the 2,239 stock options are reported with transaction code A, indicating grants or awards given at no cash cost per share in this Form 4 filing.

What is the significance of the vesting tied to Repligen (RGEN) shareholders’ next annual meeting?

Both the restricted stock units and option award vest on the earlier of a fixed date or the next annual shareholder meeting. Tying vesting to the meeting aligns director compensation with the company’s annual governance cycle and the director’s continued board service.